본문 바로가기
KERD
논문KCI 등재

Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer

김태중|최철훈|박원|조원경|이유영|김병기|조영석|이정원|배덕수|김나리
대한암학회 (Korean Cancer Association)|2021.07|Cancer Research and Treatment|제53권 제3호|pp. 803-812|DOI 10.4143/crt.2020.1251

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

RadiotherapyUterine cervical neoplasmsFluorodeoxyglucose F18Image-guided brachytherapy
주제분류의학일반

초록

Purpose This study aimed to identify the prognostic value of early metabolic response assessed using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiation therapy (RT) for cervical cancer.Materials and Methods We identified 116 patients treated with definitive RT, including FDG-PET/CT–guided intracavitary brachytherapy, between 2009 and 2018. We calculated parameters including maximum (SUVmax) and mean standardized uptake values (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for baseline FDG-PET/CT (PETbase) and image-guided brachytherapy planning FDG-PET/CT (PETIGBT). Multivariable analyses of disease-free survival (DFS) and overall survival (OS) were performed.Results We observed a time-dependent decrease in PET parameters between PETbase and PETIGBT; ΔSUVmax, ΔSUVmean, ΔMTV, and ΔTLG were 65%, 61%, 78%, and 93%, respectively. With a median follow-up of 59.5 months, the 5-year DFS and OS rates were 66% and 79%, respectively. Multivariable analysis demonstrated that ΔSUVmax ≥ 50% was associated with favorable DFS (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.14 to 5.77) and OS (HR, 5.14; 95% CI, 1.55 to 17.01). Patients with ΔSUVmax ≥ 50% (n=87) showed better DFS and OS than those with ΔSUVmax < 50% (n=29) (DFS, 76% vs. 35%, p < 0.001; OS, 90% vs. 41%, p < 0.001, respectively). Adenocarcinoma was frequently observed in ΔSUVmax < 50% compared to ΔSUVmax ≥ 50% (27.6% vs. 10.3%, p=0.003). In addition, models incorporating metabolic parameters showed improved accuracy for predicting DFS (p=0.012) and OS (p=0.004) than models with clinicopathologic factors.Conclusion Changes in metabolic parameters, especially those in SUVmax by > 50%, can help improve survival outcome predictions for patients with cervical cancer treated with definitive RT.

Abstract

Purpose This study aimed to identify the prognostic value of early metabolic response assessed using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) during radiation therapy (RT) for cervical cancer.Materials and Methods We identified 116 patients treated with definitive RT, including FDG-PET/CT–guided intracavitary brachytherapy, between 2009 and 2018. We calculated parameters including maximum (SUVmax) and mean standardized uptake values (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) for baseline FDG-PET/CT (PETbase) and image-guided brachytherapy planning FDG-PET/CT (PETIGBT). Multivariable analyses of disease-free survival (DFS) and overall survival (OS) were performed.Results We observed a time-dependent decrease in PET parameters between PETbase and PETIGBT; ΔSUVmax, ΔSUVmean, ΔMTV, and ΔTLG were 65%, 61%, 78%, and 93%, respectively. With a median follow-up of 59.5 months, the 5-year DFS and OS rates were 66% and 79%, respectively. Multivariable analysis demonstrated that ΔSUVmax ≥ 50% was associated with favorable DFS (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.14 to 5.77) and OS (HR, 5.14; 95% CI, 1.55 to 17.01). Patients with ΔSUVmax ≥ 50% (n=87) showed better DFS and OS than those with ΔSUVmax < 50% (n=29) (DFS, 76% vs. 35%, p < 0.001; OS, 90% vs. 41%, p < 0.001, respectively). Adenocarcinoma was frequently observed in ΔSUVmax < 50% compared to ΔSUVmax ≥ 50% (27.6% vs. 10.3%, p=0.003). In addition, models incorporating metabolic parameters showed improved accuracy for predicting DFS (p=0.012) and OS (p=0.004) than models with clinicopathologic factors.Conclusion Changes in metabolic parameters, especially those in SUVmax by > 50%, can help improve survival outcome predictions for patients with cervical cancer treated with definitive RT.

참고문헌 (30)

  1. Herrera FG, "The role of PET", CT in cervical cancer, 2013, pp.3, 34~
  2. Nam H, "18Ffluorodeoxyglucose positron emisson tomography", computed tomography guided conformal brachytherapy for cervical cancer, 2012, pp.84, e29~34
  3. Oh D, "Clinical outcomes in cervical cancer patients treated by FDG-PET", CTbased 3-dimensional planning for the first brachytherapy session, 2016, pp.95, e3895~
  4. Engin G, "Cervical cancer : MR imaging findings before, during, and after radiation therapy", Eur Radiol, 16, pp.313~324 (2006)
  5. Yoon JW, "PET", CT response criteria(European Organization for Research and Treatment of Cancer)predict survival better than response evaluation criteria in solid tumors in locally advanced cervical cancer treated with chemoradiation, 2016, pp.41, 677~682
  6. Lordick F, "PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction : the MUNICON phase II trial", Lancet Oncol, 8, pp.797~805 (2007)
  7. Kim N, "Prognostic values of mid-radiotherapy(18)F-FDG PET", CT in patients with esophageal cancer, 2019, pp.14, 27~
  8. Kim N, "Predictive value of interim 18FFDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy", PLoS One, 15, pp.e0236350~ (2020)
  9. 김수지, "Prognostic value of FDG PET", CT during radiotherapy in head and neck cancer patients, 2018, pp.36(2), 95~102[DOI]
  10. Haie-Meder C, "Recommendations from Gynaecological(GYN)GEC-ESTRO Working Group(I) : concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV", Radiother Oncol, 74, pp.235~245 (2005)
  11. Kidd EA, "Changes in cervical cancer FDG uptake during chemoradiation and association with response", Int J Radiat Oncol Biol Phys, 85, pp.116~122 (2013)
  12. Lin LL, "FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer", Int J Radiat Oncol Biol Phys, 65, pp.177~181 (2006)
  13. Schwarz JK, "18-F-Fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer", Int J Radiat Oncol Biol Phys, 72, pp.1502~1507 (2008)
  14. Leseur J, "Pre-and per-treatment 18F-FDG PET", CT parameters to predict recurrence and survival in cervical cancer, 2016, pp.120, 512~518
  15. Oh D, "Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography", computed tomography during concurrent chemoradiation therapy for cervical cancer, 2013, pp.87, 549~554
  16. -fluorodeoxyglucose positron emission tomography, "computed tomography", Eur Radiol, 29, pp.6741~6749 (2019)
  17. Kidd EA, "The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival", Cancer, 110, pp.1738~1744 (2007)
  18. Kidd EA, "Lymph node staging by positron emission tomography in cervical cancer : relationship to prognosis", J Clin Oncol, 28, pp.2108~2113 (2010)
  19. Kidd EA, "Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer", Int J Radiat Oncol Biol Phys, 77, pp.1085~1091 (2010)
  20. Nam H, "The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI", Gynecol Oncol, 107, pp.320~325 (2007)
  21. Fields EC, "A practical review of magnetic resonance imaging for the evaluation and management of cervical cancer", Radiat Oncol, 11, pp.15~ (2016)
  22. Sun C, "Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer : a multicentre study", EBioMedicine, 46, pp.160~169 (2019)
  23. Wormald BW, "Radiomic features of cervical cancer on T2-and diffusion-weighted MRI : prognostic value in low-volume tumors suitable for trachelectomy", Gynecol Oncol, 156, pp.107~114 (2020)
  24. Lucia F, "Prediction of outcome using pretreatment(18)FFDG PET", CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy, 2018, pp.45, 768~786
  25. Lucia F, "External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy", Eur J Nucl Med Mol Imaging, 46, pp.864~877 (2019)
  26. Lee JH, "Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients : a multi-institutional retrospective analysis of KROG 16-01", Gynecol Oncol, 147, pp.577~584 (2017)
  27. 양경미, "Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer", Radiation oncology journal, 35(1), pp.39~47 (2017), 대한방사선종양학회
  28. Noh JM, "Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy : a multicenter retrospective study(KROG 13-10)", Gynecol Oncol, 132, pp.618~623 (2014)
  29. Hodgson A, "Cervical adenocarcinomas : a heterogeneous group of tumors with variable etiologies and clinical outcomes", Arch Pathol Lab Med, 143, pp.34~46 (2019)
  30. Hautzel H, "Early changes in fluorine18-FDG uptake during radiotherapy", J Nucl Med, 38, pp.1384~1386 (1997)

관련 논문AI추천

Assessment of Tumor Regression by Consecutive Pelvic Magnetic Resonance Imaging and Dose Modification during High- Dose-Rate Brachytherapy for Carcinoma of the Uterine Cervix김석모, 나병식, 남택근, 송주영, 안성자, 윤미선, 정웅기, 최호선대한암학회 · Cancer Research and Treatment2005 · 제37권 제3호Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period강성희, 강현철, 김경수, 김재원, 김학재, 김희승, 박노현, 송용상, 엄근용, 위찬우, 이태훈, 정현훈, 최창헌, 이마리아대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy박희철, Akio Yonesaka, Hiroki Shirato, Hiroshi Taguchi, Kazuhiko Tsuchiya, Masayori Ishikawa, Noriaki Sakuragi, Norio Katoh, Rumiko Kinoshita, Shinichi Shimizu, Yasuhiko Ebina연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제1호Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation (CCRT) for Cervical Cancer on Overall Survival박원, 김병기, 김보미, 김태중, 노경원, 배덕수, 이유영, 이정원, 조원경, 최철훈대한암학회 · Cancer Research and Treatment2022 · 제54권 제1호Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review김성환, 김애란, 이성종, 이세원, 이종훈대한암학회 · Cancer Research and Treatment2024 · 제56권 제1호Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy배진영, 설기호, 오진주, 이정원, YounSeokChoi영남대학교 의과대학 · Journal of Yeungnam Medical Science2019 · 제36권 제2호

이 간행물의 다른 논문 (30건)

The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer?지의규, 안용찬pp. 609-610Physical and Biological Characteristics of Particle Therapy for Oncologists변화경, 양경미, 김진성, 유규상, 금웅섭, 김용배, 한민철pp. 611-620Who Will Benefit from Charged-Particle Therapy?우홍균, 김경수pp. 621-634Technological Advances in Charged-Particle Therapy박종민, 우홍균, 김정인pp. 635-640Depression, Rather Than Cancer-Related Fatigue or Insomnia, Decreased the Quality of Life of Cancer Patients김화정, 이주희, 김규민, 정석훈, 여성욱pp. 641-649
원문 보기